Circulating SH2B1 is associated with an increased risk of gastric cancer

Abstract

Abstract. Gastric cancer (GC) is one of the most common types of cancer in humans and the second leading cause of cancer-associated mortality worldwide. Identifying novel risk factors will facilitate the development of therapeutic strategies to prevent and treat GC. Increased expression of the Src homology 2 B adaptor protein 1 (SH2B1) may stimulate the malignant progression of lung cancer, esophageal cancer and neuroblastoma. However, its function in GC has not yet been investigated. To identify whether increased serum SH2B1 is a risk factor for GC, the present study performed a nested case-control study of patients within the Chinese cohort study. Levels of serum SH2B1 were measured in 563 patients diagnosed with GC during the follow-up period and in 1,126 matched healthy controls. The results demonstrated that high levels of serum SH2B1 were associated with an increased GC risk (odds ratio, 3.23; 95% confidence interval, 2.45-5.65). When analyses were stratified further by sex, age and smoking, an association between increased levels of SH2B1 and GC was identified in males but not in females. Furthermore, the association between SH2B1 levels and GC was more evident in younger than in older participants, and statistically significant in current smokers but not in nonsmokers. These results were not altered following the exclusion of outliers. Furthermore, it was demonstrated that overexpression of SH2B1 contributes to the malignant transformation of normal gastric epithelial cells. Thus, the present study demonstrated that elevated serum SH2B1 levels may increase the risk of GC.

Hsa_circ_0075960 Serves as a Sponge for miR-361-3p/SH2B1 in Endometrial Carcinoma

“… 23 Accumulative evidence have proven that SH2B1 is not only associated with metabolic diseases, such as diabetes, but also with cancer progression. 24 - 28 From the cancer cell line encyclopedia and human protein atlas, SH2B1 was demonstrated to be expressed in the endometrium with higher expression levels in EC; this report is consistent with those of our unpublished study. From the TCGA dataset, the 5-year survival rate of the patients with high SH2B1 expression was 68%, while that of patients with low SH2B1 expression was 80%, suggesting that SH2B1 may have unfavorable influences on the prognosis of patients with EC.…”

“…A series of papers have been published that uncovered the role of SH2B1 in the occurrence, progression, and worsening of colorectal cancer, gastric cancer, and NSCLC. 19 , 27 , 29 In conclusion, we identified a novel biomarker of the EC progression circRNA hsa_circ_0075960, which served as a sponger of miR-361-3p to regulate the expression of SH2B1.…”

BBOX1‐AS1 contributes to colorectal cancer progression by sponging hsa‐miR‐361‐3p and targeting SH2B1

“…With further exploration of molecular mechanism in present study, we found that BBOX1-AS1 was mainly distributed in the cytoplasm of CRC cells an oncogene in multiple cancers. For example, SH2B1 was identified as a risk factor in gastric cancer and stimulated its progression [24]. SH2B1 enhanced EMT process in lung adenocarcinoma through IRS1/β-catenin axis [25].…”

“…SH2B1 was commonly recognized as an oncogene in multiple cancers. For example, SH2B1 was identified as a risk factor in gastric cancer and stimulated its progression [24]. SH2B1 enhanced the EMT process in lung adenocarcinoma through the IRS1/β‐catenin axis [25].…”

High expression of SH2B adaptor protein 1 (SH2B1) indicates poor prognosis in colorectal cancer

“…There are several views on this issue. First, it has been confirmed that SH2B1 can regulate cell migration, proliferation and differentiation in vitro [10,17,18], but the mechanism is still unclear. Second, SH2B1 may be involved in the regulation of oxidative stress which can promote the development and progress of many aspects of cancer [19,20].…”